Exhibit 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the filing with the Securities and Exchange Commission of the Annual Report of Candel Therapeutics, Inc. (the “Company”) on Form 10-K for the period ended December 31, 2023 (the “Report”), the undersigned President and Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to his knowledge:
1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: March 28, 2024 | By: | /s/ Paul Peter Tak | |
Paul Peter Tak | |||
President and Chief Executive Officer (principal executive officer) |
In connection with the filing with the Securities and Exchange Commission of the Annual Report of Candel Therapeutics, Inc. (the “Company”) on Form 10-K for the period ended December 31, 2023 (the “Report”), the undersigned Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to his knowledge:
1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: March 28, 2024 |
| By: | /s/ Charles Schoch |
|
|
| Charles Schoch |
|
|
| Interim Chief Financial Officer (principal financial officer and principal accounting officer) |
